申请人:Merck Sharp & Dohme Corp.
公开号:US09493474B2
公开(公告)日:2016-11-15
This invention relates to compounds of Formula I having the following general structure:
Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2
wherein R represents a fused bicyclic or spirocyclic aliphatic diamine and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
这项发明涉及具有以下一般结构的Formula I化合物:Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2,其中R代表融合的双环或螺环脂肪二胺及其药用可接受的盐,这些化合物是肾外髓钾(ROMK)通道(Kir1.1)的抑制剂。这些化合物可用作利尿剂和排钠剂,因此可用于治疗和预防由过多盐分和水分潴留引起的疾病,包括高血压和慢性和急性心力衰竭等心血管疾病。